For older adults taking aspirin to prevent heart attacks or strokes, taking 50 mg per day does not increase the risk of major cardiovascular events compared to taking 100 mg per day, whether they have had prior heart disease or not.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review of RCTs would determine whether 50 mg aspirin consistently provides non-inferior cardiovascular protection compared to 100 mg across diverse elderly populations.
A systematic review and meta-analysis of all randomized trials comparing 50 mg and 100 mg aspirin in adults aged 60+ with or without CVD, including at least 15,000 participants with minimum 3-year follow-up, measuring MACE as primary endpoint, with non-inferiority margins pre-specified at HR ≤1.25.
A randomized trial would determine whether assigning older adults to 50 mg versus 100 mg aspirin directly causes equivalent cardiovascular protection.
A double-blind, multicenter RCT of 6,000 adults aged 60–85 with cardiovascular risk factors or established CVD, randomized 1:1 to 50 mg or 100 mg aspirin daily for at least 3 years, with primary endpoint of first MACE (MI, stroke, cardiovascular death), and secondary endpoints of all-cause mortality and hospitalizations.
A longer-term cohort with more complete follow-up could confirm whether the observed equivalence in MACE persists beyond the current 183-day median follow-up.
A prospective multicenter cohort of 12,000 older adults initiating aspirin therapy, with annual assessments of aspirin dose, adherence, and MACE events adjudicated by independent reviewers over 5 years, adjusting for time-varying confounders such as statin initiation or renal decline.
A case-control study could assess whether prior exposure to 50 mg versus 100 mg aspirin is less common among those who later experienced MACE than among matched controls.
A nested case-control study within the LAPIS cohort comparing 300 patients with MACE to 600 matched controls without MACE, assessing prior aspirin dose, duration, and adherence, with exposure data collected prospectively and blinded to outcome.
A cross-sectional survey could estimate the prevalence of MACE among older adults currently taking 50 mg versus 100 mg aspirin, but cannot determine whether dose caused the event.
A national survey of 15,000 older adults taking aspirin, collecting self-reported history of MI, stroke, or cardiovascular death and current aspirin dose via structured interviews and medical record review, with validation of events via hospital discharge codes.